ClinicalTrials.gg
TerminatedNCT01536015ROADMAPUpdated Aug 1, 2014Results posted

Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction

A Phase 3 interventional study of Rotigotine and Placebo in Advanced Parkinson's Disease, sponsored by UCB Pharma. Terminated at 26 sites in United States. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2014-08-01.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was stopped due to low enrollment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Enrollment
39th of 42
25 · median 123
Started
2012
with 7 others
Phase 3
20 of 44
none open now
Registered
22nd of 44
by date
Lead sponsor
22 of 44
UCB Pharma

Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 39th largest by enrollment of the 42 interventional ones that give a count, is one of 8 that started in 2012, is one of 20 in phase 3, and was the 22nd registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

The primary purpose is to demonstrate superiority of Rotigotine over Placebo on motor symptoms when used in subjects with symptoms of Gastrointestinal Dysfunction. Hypothesis: Rotigotine will decrease OFF time compared to Placebo.

03

Conditions studied

  • Advanced Parkinson's Disease

Browse trials for

Keywords

  • Rotigotine
  • Neupro®
  • Levodopa
  • Gastrointestinal Dysfunction
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is informed and given ample time and opportunity to think about his/her participation in this study and has given his/her written on an Institutional Review Board approved consent form
  • Subject is willing and able to comply with all study requirements (protocol, visit schedule, procedures, and medication application)
  • Subject is male or female and ≥ 30 years of age
  • Subject has Idiopathic Parkinson's Disease of more than 3 years duration, as defined by the cardinal sign, bradykinesia, plus the presence of at least 1 of the following: resting tremor, rigidity, impairment of postural reflexes; and is without any other known or suspected cause of Parkinsonism
  • Subject has a Hoehn \& Yahr stage score II through IV
  • Subject must be on a stable dose of L-dopa, either short-acting or sustained release (in combination with Benserazide or Carbidopa), of at least 200 mg/day administered in at least 2 intakes, for at least 21 days prior to starting Parkinson's diaries
  • Subject must be able to differentiate between the "on" and "off" state (and thereby be able to recognize the Time To "On" (TTON)), and be willing and able to accurately complete a Parkinson's Disease subject diary on designated days (with assistance from caregivers, if required)
  • Subject must complete 6 Parkinson's diaries over a period of 6 days, with 4 of the 6 Parkinson's diaries being "valid" as determined by the investigator. The "valid" Parkinson's diaries confirm that the subject has an average of at least 2.5 h/day spent in the "off" state
  • Subject receiving a Monoamine Oxidase (MAO)-B Inhibitor (eg, Selegiline or Rasagiline), an n-Methyl-d-Aspartate Antagonist (eg, Amantadine), or allowed anti-Parkinson medications and has been on a stable dose for at least 21 days prior to starting Parkinson's diaries and is anticipated to be maintained on that dose for the duration of the study
  • Subject has clinical symptoms of Gastrointestinal Dysfunction (GID) confirmed by at least 1 of the following

    •Parkinson's disease-related GI symptoms as per the Gastrointestinal Degenerative Scale (GIND) Scale: defecatory dysfunction, constipation, excessive gas, abdominal pain, bloating, nausea, vomiting, anorexia, early satiety, or weight loss (except sialorrhea and dysphagia)

  • Female subjects of must agree to use 1 of the following methods: oral contraceptive, intrauterine device, or double-barrier method, throughout the study and for 2 weeks after the removal of study medication

Exclusion criteria

Exclusion Criteria:

  • Subject has previously participated in this study
  • Subject has participated in another study of an medicinal product (IMP) or a medical device within the last 30 days or is currently participating in another study of an IMP or a medical device
  • Subject has an Atypical Parkinsonian Syndrome due to drugs (eg, Metoclopramide, Flunarizine), Metabolic Neurogenetic Disorders (eg, Wilson's Disease), Encephalitis, Cerebrovascular Disease, or Degenerative Disease (eg, Progressive Supranuclear Palsy)
  • Subject has a history of Pallidotomy, Thalamotomy, Deep Brain Stimulation, or Fetal Tissue Transplant
  • Subject has Dementia, Active Psychosis, or Hallucinations
  • Subject exhibits Dopaminergic Dysregulation Syndrome
  • Subject is receiving therapy with certain medications in a specific timeframe as specified in the protocol
  • Subject has history of chronic Gastrointestinal (GI) Disease not related to Parkinson's disease which in the judgement of the investigator may affect the ability of the subject to participate in the study (ie, Irritable Bowel Syndrome, Diverticulitis, Crohn's Disease, etc) or GI/abdominal surgery (except for Appendectomy, Hysterectomy, or Cholecystectomy)
  • Subject has had any GI surgery in the 3 months prior to the Screening Visit
  • Subject has a current diagnosis of Epilepsy, has a history of seizures as an adult, or has a history of stroke or within 1 year prior to the Screening Visit
  • Subject has Hepatic or Renal Dysfunction
  • Subject has clinically relevant Cardiac Dysfunction (any cardiac disorder that in the opinion of the investigator would put the subject at risk of clinically relevant arrhythmia)
  • Subject has had a Myocardial Infarction within the last 1 year prior to the Screening Visit
  • Subject has a history of Symptomatic (not Asymptomatic) Orthostatic Hypotension
  • Subject has a Systolic Blood Pressure (BP) \< 105 mmHg at the Screening Visit
  • Subject has a history of chronic alcohol or drug abuse within the prior 6 months
  • Female subject is pregnant or lactating
  • Subject (male or female) is of child bearing potential but not surgically sterile or not using adequate methods
  • Subject has evidence of an Impulse Control Disorder according to the Modified Minnesota Impulsive Disorders Interview (mMIDI) at the Screening Visit
  • Subject has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ('Yes') to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at the Screening Visit
  • Subject has a significant skin disease/condition that would make transdermal drug use inappropriate, including a history of skin sensitivity to adhesives or other transdermal medications
  • Subject has a known to any components of the Rotigotine patch, including Sodium Metabisulfite
  • Subject has any medical, psychiatric, or cognitive condition, or laboratory abnormality that would, in the opinion of the investigator, jeopardize or compromise the subject's well-being or ability to participate in the study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Rotigotine

    Rotigotine patch titrated from 4 mg/24 h - 8 mg/24 h or until effective or maximum dose is reached.

    Drug: Rotigotine

  • Placebo comparator
    Placebo

    Placebo patch.

    Drug: Placebo

Interventions

  • Strength and Form: 4 - 8 mg patches, one patch applied every 24 hours Dosage and Frequency: One patch every 24 hours Duration: 10 weeks

    Also known as: Neupro®

  • DrugPlacebo

    Frequency: One patch applied every 24 hours Duration: 10 weeks

06

What researchers measure

Primary outcomes

  1. Change in Rotigotine Versus Placebo in the Absolute Time Spent "Off" From Baseline to the End of the 7-week Maintenance Period

    Mean number of hours marked "off" during a 24-hour period.

    Time frame: Baseline to 10 weeks

Secondary outcomes

  1. Change in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS UPDRS) Part III (Motor Examination) in the "on" State From Baseline to the End of the 7-week Maintenance Period

    The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS UPDRS) Part III is an 18-item scale with each single item of the scale ranging from 0 (normal) to 4 (severe).

    Time frame: Baseline to 10 weeks

  2. Change in Predictability of "Off" Time (Using MDS UPDRS Part IV Item 4.5) From Baseline to End of the 7-week Maintenance Period

    The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS UPDRS) Part IV is a 6-item scale with each single item of the scale ranging from 0 (normal) to 4 (severe).

    Time frame: Baseline to 10 weeks

  3. Change in Score on Gastrointestinal Neurodegenerative Scale (GIND) From Baseline to the End of the of the 7-week Maintenance Period

    Gastrointestinal Neurodegenerative Scale (GIND) is an 18-item scale measuring gastrointestinal dysfunction with each single item of the scale ranging from 0 (never or not at all) to 5 (very severe).

    Time frame: Baseline to 10 weeks

  4. Change in Score on Fatigue Severity Scale (FSS) From Baseline to the End of 7-week Maintenance Period

    The Fatigue Severity Scale is a 9-item scale measuring the impact of fatigue on everyday functioning (e.g. "fatigue interferes with my work, each single item of the scale ranging from 1 (disagree) to 7 (agree).

    Time frame: Baseline to 10 weeks

  5. Change in Score on Parkinson's Disease Questionnaire (PDQ8) From Baseline to the End of 7-week Maintenance Period

    The Parkinson's Disease Questionnaire (PDQ-8) is a self-administered 8-item questionnaire that assesses issues associated with Parkinson's disease. Each single item of the 8-item questionnaire ranges from 0 (never) to 4 (always).

    Time frame: Baseline to 10 weeks

07

Results

Posted Aug 1, 2014

Participant flow

The total duration of the study was to be a maximum of 19 weeks for each subject, including the Screening Period (within 50 days prior to Day 1), the Titration Period (up to 3 weeks), the Maintenance Period (up to 7 weeks), and a Safety Follow-Up Visit. The Participant Flow refers to the Randomized Set which includes all randomized subjects.

Participant flow — Overall Study
MilestonePlaceboRotigotine
Started1213
Completed43
Not completed810
Withdrew: Adverse event14
Withdrew: Lost to follow-up01
Withdrew: Inclusion criterion not met20
Withdrew: Study closure55

Outcome measures

PrimaryChange in Rotigotine Versus Placebo in the Absolute Time Spent "Off" From Baseline to the End of the 7-week Maintenance Period

Mean number of hours marked "off" during a 24-hour period.

Time frame:
Baseline to 10 weeks

No measurements were reported for this outcome.

SecondaryChange in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS UPDRS) Part III (Motor Examination) in the "on" State From Baseline to the End of the 7-week Maintenance Period

The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS UPDRS) Part III is an 18-item scale with each single item of the scale ranging from 0 (normal) to 4 (severe).

Time frame:
Baseline to 10 weeks

No measurements were reported for this outcome.

SecondaryChange in Predictability of "Off" Time (Using MDS UPDRS Part IV Item 4.5) From Baseline to End of the 7-week Maintenance Period

The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS UPDRS) Part IV is a 6-item scale with each single item of the scale ranging from 0 (normal) to 4 (severe).

Time frame:
Baseline to 10 weeks

No measurements were reported for this outcome.

SecondaryChange in Score on Gastrointestinal Neurodegenerative Scale (GIND) From Baseline to the End of the of the 7-week Maintenance Period

Gastrointestinal Neurodegenerative Scale (GIND) is an 18-item scale measuring gastrointestinal dysfunction with each single item of the scale ranging from 0 (never or not at all) to 5 (very severe).

Time frame:
Baseline to 10 weeks

No measurements were reported for this outcome.

SecondaryChange in Score on Fatigue Severity Scale (FSS) From Baseline to the End of 7-week Maintenance Period

The Fatigue Severity Scale is a 9-item scale measuring the impact of fatigue on everyday functioning (e.g. "fatigue interferes with my work, each single item of the scale ranging from 1 (disagree) to 7 (agree).

Time frame:
Baseline to 10 weeks

No measurements were reported for this outcome.

SecondaryChange in Score on Parkinson's Disease Questionnaire (PDQ8) From Baseline to the End of 7-week Maintenance Period

The Parkinson's Disease Questionnaire (PDQ-8) is a self-administered 8-item questionnaire that assesses issues associated with Parkinson's disease. Each single item of the 8-item questionnaire ranges from 0 (never) to 4 (always).

Time frame:
Baseline to 10 weeks

No measurements were reported for this outcome.

Adverse events

Collected over From Screening (Day -50 to Day -1) up to the Safety Follow-up Visit (14±2 days after the End of Maintenance/Start of De-Escalation Visit or Premature Withdrawal/Start of De-Escalation Visit).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/12 (0%)4/12 (33.3%)
Rotigotine—1/13 (7.7%)5/13 (38.5%)
Most frequent serious events
Most frequent serious events
EventPlaceboRotigotine
Ankle fractureInjury, poisoning and procedural complications0/121/13
Skin lacerationInjury, poisoning and procedural complications0/121/13
Decubitus ulcerSkin and subcutaneous tissue disorders0/121/13
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPlaceboRotigotine
HeadacheNervous system disorders2/120/13
DyskinesiaNervous system disorders1/122/13
Abdominal painGastrointestinal disorders1/120/13
VomitingGastrointestinal disorders1/120/13
Pain in extremityMusculoskeletal and connective tissue disorders1/121/13
ParaesthesiaNervous system disorders1/120/13
DyspepsiaGastrointestinal disorders0/121/13
Wound infection staphylococcalInfections and infestations0/121/13
Brain contusionInjury, poisoning and procedural complications0/121/13
Traumatic brain injuryInjury, poisoning and procedural complications0/121/13

Baseline characteristics

The Analysis Population Description refers to the Safety Set (SS) which consists of all randomized subjects who received at least one dose of study medication.

Age, Continuous
Age, Continuous(years)PlaceboRotigotineTotal
Mean66.1 ± 8.266.7 ± 9.666.4 ± 8.8
Age, Categorical
Age, Categorical(Participants)PlaceboRotigotineTotal
<=18 years000
Between 18 and 65 years5611
>=65 years7714
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRotigotineTotal
Female437
Male81018
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboRotigotineTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American044
White11819
More than one race112
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)PlaceboRotigotineTotal
United States121325
Weight
Weight(kilogram)PlaceboRotigotineTotal
Mean84.64 ± 14.9376.67 ± 19.5380.50 ± 17.58
Height
Height(centimeter)PlaceboRotigotineTotal
Mean171.79 ± 13.65173.86 ± 10.61172.87 ± 11.95
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram/m^2)PlaceboRotigotineTotal
Mean28.714 ± 4.16725.113 ± 4.80926.842 ± 4.785
08

Study locations

26 sites
  • 011
    Birmingham, Alabama, United States
  • 001
    Gilbert, Arizona, United States
  • 022
    Fountain Valley, California, United States
  • 017
    Irvine, California, United States
  • 028
    Pasadena, California, United States
  • 015
    Sunnyvale, California, United States
  • 008
    Gainesville, Florida, United States
  • 009
    Miami, Florida, United States
  • 010
    Ormond Beach, Florida, United States
  • 006
    Sunrise, Florida, United States
  • 032
    Annapolis, Maryland, United States
  • 027
    Lincoln, Nebraska, United States
  • 016
    Commack, New York, United States
  • 026
    Mineola, New York, United States
  • 034
    Charlotte, North Carolina, United States
  • 002
    Raleigh, North Carolina, United States
  • 007
    Salisbury, North Carolina, United States
  • 021
    Toledo, Ohio, United States
  • 023
    Tulsa, Oklahoma, United States
  • 031
    Cordova, Tennessee, United States
  • 018
    Memphis, Tennessee, United States
  • 014
    Houston, Texas, United States
  • 030
    Richmond, Virginia, United States
  • 003
    Virginia Beach, Virginia, United States
  • 012
    Kirkland, Washington, United States
  • 013
    Milwaukee, Wisconsin, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2012
First posted
Feb 20, 2012
Start
Jan 2012
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results first posted
Aug 1, 2014
Last update
Aug 1, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01536015
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Feb 20, 2012
Start date
Jan 2012
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Aug 1, 2014
Last update
Aug 1, 2014

Study contacts

UCB Clinical Trial Call Center
study director · 877-822-9493

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion